A biodegradable lipid nanoparticle delivers a Cas9 ribonucleoprotein for efficient and safe in situ genome editing in melanoma
- 24 October 2024
- journal article
- research article
- Published by Elsevier in Acta Biomaterialia
- Vol. 190, 531-547
Abstract
No abstract availableKeywords
Funding Information
- State Key Laboratory of Biocatalysis and Enzyme Engineering (SKLBEE20230013)
- Chengdu Medical College (2024qnGzn12)
- National Natural Science Foundation of China (82104084)
- National Natural Science Foundation of China (32070171)
This publication has 42 references indexed in Scilit:
- Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developmentsWIREs Nanomedicine and Nanobiotechnology, 2023
- Graphene-encapsulated iron nanoparticles as a non-viral vector for gene delivery into melanoma cellsBiochemical and Biophysical Research Communications, 2023
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challengesActa Pharmaceutica Sinica B, 2021
- CRISPR/Cas gene therapyJournal of Cellular Physiology, 2020
- Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scaleInternational Journal of Pharmaceutics, 2020
- Melanoma treatment: from conventional to nanotechnologyJournal of Cancer Research and Clinical Oncology, 2018
- Prospects of Gene Therapy to Treat Melanoma2018
- Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applicationsJournal of Controlled Release, 2017
- Frequency of and risk factors for tumor upstaging after wide local excision of primary cutaneous melanomaJournal of the American Academy of Dermatology, 2017